Investigational cell therapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have an advanced solid tumor (like pancreatic, colorectal, or lung cancer) that has progressed after standard treatment or you couldn't tolerate standard treatment.
- You must have a specific genetic marker (HLA-A*11:01) and not another (HLA-A*68:01).
- Your tumor must have a KRAS or NRAS G12D gene mutation.
- You must have at least one measurable tumor on scans (like CT or MRI).
- You must be generally active and able to care for yourself (ECOG score 0-1) and have a life expectancy of more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
This trial tests an experimental cell therapy that uses your own immune cells to attack cancers with a specific gene change (KRAS G12V). It may be an option if other treatments haven't worked.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a new treatment using your own immune cells (T cells) that are modified to find and attack cancer cells with a specific genetic change (KRAS G12V or G12D). It is for people with advanced cancer that has not responded to standard treatments.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.